MX389847B - Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. - Google Patents

Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.

Info

Publication number
MX389847B
MX389847B MX2019015311A MX2019015311A MX389847B MX 389847 B MX389847 B MX 389847B MX 2019015311 A MX2019015311 A MX 2019015311A MX 2019015311 A MX2019015311 A MX 2019015311A MX 389847 B MX389847 B MX 389847B
Authority
MX
Mexico
Prior art keywords
compositions
acid esters
cannabidiolic acid
cannabidiolic
symptoms
Prior art date
Application number
MX2019015311A
Other languages
English (en)
Other versions
MX2019015311A (es
Inventor
Aron Weller
Christeen Haj
Joseph Tam
Linda Parker
Raphael Mechoulam
Reem Smoum
Roger Pertwee
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Univ Bar Ilan
Univ Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd, Univ Bar Ilan, Univ Guelph filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2019015311A publication Critical patent/MX2019015311A/es
Publication of MX389847B publication Critical patent/MX389847B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esteres de ácido cannabidiólico, composiciones que las comprenden y usos de las mismas en el tratamiento de varias enfermedades, condiciones y síntomas.
MX2019015311A 2017-06-20 2018-06-20 Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. MX389847B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (2)

Publication Number Publication Date
MX2019015311A MX2019015311A (es) 2022-02-02
MX389847B true MX389847B (es) 2025-03-20

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015311A MX389847B (es) 2017-06-20 2018-06-20 Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.

Country Status (12)

Country Link
US (1) US11440870B2 (es)
EP (1) EP3509638B1 (es)
JP (1) JP2020524679A (es)
CN (2) CN111032088A (es)
AU (1) AU2018287018B2 (es)
BR (1) BR112019026916A2 (es)
CA (1) CA3067512A1 (es)
DK (1) DK3509638T3 (es)
ES (1) ES2909350T3 (es)
MX (1) MX389847B (es)
PT (1) PT3509638T (es)
WO (1) WO2018235079A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN111032088A (zh) 2017-06-20 2020-04-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻二酚酸酯类组合物及其用途
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
BR112021012420A2 (pt) * 2018-12-25 2021-09-08 Epm (Ip), Inc. Ésteres de ácido canabidiólico para composições cosméticas ou comestíveis
CN118831076A (zh) * 2019-03-12 2024-10-25 Epm (Ip)公司 大麻素酸酯组合物及其用途
JP2022545491A (ja) 2019-08-22 2022-10-27 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
EP4243602A4 (en) 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022137144A1 (en) * 2020-12-24 2022-06-30 Buzzelet Development And Technologies Ltd. Compositions comprising cannabinoid acid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) * 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
WO1999057107A2 (en) 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
WO2006002050A1 (en) 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
CN102766128A (zh) * 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
ES2547354T3 (es) * 2013-09-03 2015-10-05 Symrise Ag Mezclas de compuestos cannabinoides, su preparación y uso
MX352386B (es) * 2014-04-16 2017-11-22 Vivacell Biotechnology Espana S L Nuevos derivados quinona de cannabidiol.
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
CN111032088A (zh) 2017-06-20 2020-04-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻二酚酸酯类组合物及其用途
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
US11440870B2 (en) 2022-09-13
EP3509638A1 (en) 2019-07-17
CN111032088A (zh) 2020-04-17
AU2018287018B2 (en) 2022-04-28
ES2909350T3 (es) 2022-05-06
DK3509638T3 (da) 2022-04-11
JP2020524679A (ja) 2020-08-20
BR112019026916A2 (pt) 2020-06-30
AU2018287018A1 (en) 2020-01-30
CN121534035A (zh) 2026-02-17
PT3509638T (pt) 2022-03-02
WO2018235079A1 (en) 2018-12-27
EP3509638B1 (en) 2022-01-12
US20200115317A1 (en) 2020-04-16
MX2019015311A (es) 2022-02-02
CA3067512A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2017002123A1 (es) Heterociclos biciclicos como inhibidores de fgnr
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX385845B (es) Usos y composiciones de la flagelina
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.